Anaphylatoxin C3a receptors in asthma

Respiratory Research

Volumn 6, Issue , 2005, Pages

  Ali, Hydar ^a   Panettieri Jr , Reynold A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A RECEPTOR; FC RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FC FRAGMENT; UNCLASSIFIED DRUG; ANAPHYLATOXIN; COMPLEMENT C3A RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT RECEPTOR; MEMBRANE PROTEIN;

ALLERGIC ASTHMA; BASOPHIL; BRONCHUS HYPERREACTIVITY; BRONCHUS MUSCLE; CELL ACTIVATION; CELL INTERACTION; CELL STIMULATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; EOSINOPHIL; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG LAVAGE; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PATHOGENESIS; PNEUMONIA; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SENSITIZATION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW; ANIMAL; ASTHMA; IMMUNOLOGY;

ANAPHYLATOXINS; ANIMALS; ASTHMA; COMPLEMENT C3A; HUMANS; MEMBRANE PROTEINS; RECEPTORS, COMPLEMENT;

EID: 25444435133     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1465-9921-6-19     Document Type: Review

References (57)

1. Amrani Y, Panettieri RA: Airway smooth muscle: contraction and beyond. Int J Biochem Cell Biol 2003, 35:272-276.
2. Howarth PH, Knox AJ, Amrani Y, Tliba O, Panettieri RAJ, Johnson M: Synthetic responses in airway smooth muscle. J Allergy Clin Immunol 2004, 114:S32-50.
3. Panettieri RAJ: Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 2003, 137:277-293.
4. Robinson DS: The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 2004, 114:58-65.
5. Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, Bradding P: Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003, 33:1711-1716.
6. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID: Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-1705.
7. Rivera J: Molecular adapters in Fc(epsilon)RI signaling and the allergic response. Curr Opin Immunol 2002, 14:688-693.
8. Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, Lu KT, Guo RF, Neff TA, Padgaonkar VA, Lambris JD, Spruce L, Mastellos D, Zetoune FS, Ward PA: Protection of innate immunity by C5aR antagonist in septic mice. Faseb J 2002, 16:1567-1574.
9. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, Gessner JE: C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complexinduced lung disease. J Clin Invest 2002, 110:1823-1830.
10. Hawlisch H, Wills-Karp M, Karp CL, Kohl J: The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004, 41:123-131.
11. Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H: Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003, 112:525-530.
12. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000, 406:998-1001.
13. Castro FF, Schmitz-Schumann M, Rother U, Kirschfink M: Complement activation by house dust: reduced reactivity of serum complement in patients with bronchial asthma. Int Arch Allergy Appl Immunol 1991, 96:305-310.
14. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J: Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001, 164:1841-1843.
15. Hasegawa K, Tamari M, Shao C, Shimizu M, Takahashi N, Mao XQ, Yamasaki A, Kamada F, Doi S, Fujiwara H, Miyatake A, Fujita K, Tamura G, Matsubara Y, Shirakawa T, Suzuki Y: Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004, 115:295-301.
16. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer Zu Vilsendorf A, Grove M, Klos A, Kohl J: Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma [In Process Citation]. J Immunol 2000, 165:5401-5405.
17. Gerard NP, Gerard C: Complement in allergy and asthma. Curr Opin Immunol 2002, 14:705-708.
18. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PBJ, Tack BF, Wetsel RA: Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001, 166:2025-2032.
19. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002, 169:5926-5933.
20. Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001, 167:4141-4145.
21. Vandermeer J, Sha Q, Lane AP, Schleimer RP: Innate immunity of the sinonasal cavity: expression of messenger RNA for complement cascade components and toll-like receptors. Arch Otolaryngol Head Neck Surg 2004, 130:1374-1380.
22. Varsano S, Kaminsky M, Kaiser M, Rashkovsky L: Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line. Thorax 2000, 55:364-369.
23. Strunk RC, Eidlen DM, Mason RJ: Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988, 81:1419-1426.
24. Nagata S, Glovsky MM: Activation of human serum complement with allergens. I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation. J Allergy Clin Immunol 1987, 80:24-32.
25. Maruo K, Akaike T, Ono T, Okamoto T, Maeda H: Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 1997, 100:253-260.
26. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF: Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983, 130:1891-1895.
27. Gutzmer R, Lisewski M, Zwirner J, Mommert S, Diesel C, Wittmann M, Kapp A, Werfel T: Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology 2004, 111:435-443.
28. Kirchhoff K, Weinmann O, Zwirner J, Begemann G, Gotze O, Kapp A, Werfel T: Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology 2001, 103:210-217.
29. Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, Zwirner J: IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J Immunol 2003, 170:3306-3314.
30. Werfel T, Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Gotze O, Zwirner J: Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000, 165:6599-6605.
31. Kawamoto S, Yalcindag A, Laouini D, Brodeur S, Bryce P, Lu B, Humbles AA, Oettgen H, Gerard C, Geha RS: The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J Clin Invest 2004, 114:399-407.
32. Taube C, Rha YH, Takeda K, Park JW, Joetham A, Balhorn A, Dakhama A, Giclas PC, Holers VM, Gelfand EW: Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2003, 168:1333-1341.
33. Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, Glaab T, Erpenbeck V, Krug N, Braun A: Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation. J Immunol 2005, 174:783-789.
34. Taube C, Wei X, Swasey CH, Joetham A, Zarini S, Lively T, Takeda K, Loader J, Miyahara N, Kodama T, Shultz LD, Donaldson DD, Hamelmann EH, Dakhama A, Gelfand EW: Mast cells, FcepsilonRI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004, 172:6398-6406.
35. Andrade MV, Hiragun T, Beaven MA: Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. J Immunol 2004, 172:7254-7262.
36. Furumoto Y, Nunomura S, Terada T, Rivera J, Ra C: The Fcepsilon-RIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production. J Biol Chem 2004, 279:49177-49187.
37. Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I: Regulation of mast cell activation by complement-derived peptides. Immunol Lett 2004, 92:39-42.
38. Woolhiser MR, Brockow K, Metcalfe DD: Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin Immunol 2004, 110:172-180.
39. Venkatesha RT, Thangam EB, Zaidi AK, Ali H: Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 2005, 42:581-587.
40. Ali H, Ahamed J, Hernandez-Munain C, Baron JL, Krangel MS, Patel DD: Chemokine production by G protein-coupled receptor activation in a human mast cell line: roles of extracellular signal-regulated kinase and NFAT. J Immunol 2000, 165:7215-7223.
41. Ahamed J, Venkatesha RT, Thangam EB, Ali H: C3a Enhances Nerve Growth Factor-Induced NFAT Activation and Chemokine Production in a Human Mast Cell Line, HMC-1. J Immunol 2004, 172:6961-6968.
42. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, Murphy PM: C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996, 157:1693-1698.
43. Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T: C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997, 89:2863-2870.
44. Page S, Ammit AJ, Black JL, Armour CL: Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1313-23.
45. Berger P, Girodet PO, Begueret H, Ousova O, Perng DW, Marthan R, Walls AF, Tunon de Lara JM: Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. Faseb J 2003, 17:2139-2141.
46. Carroll NG, Mutavdzic S, James AL: Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002, 19:879-885.
47. Kassel O, Schmidlin F, Duvernelle C, Gasser B, Massard G, Frossard N: Human bronchial smooth muscle cells in culture produce stem cell factor. Eur Respir J 1999, 13:951-954.
48. Tsujimura T: Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Pathol Int 1996, 46:933-938.
49. Ammit AJ, Lazaar AL, Irani C, O'Neill GM, Gordon ND, Amrani Y, Penn RB, Panettieri RAJ: Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 2002, 26:465-474.
50. Oltmanns U, Issa R, Sukkar MB, John M, Chung KF: Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 2003, 139:1228-1234.
51. Song R, Ning W, Liu F, Ameredes BT, Calhoun WJ, Otterbein LE, Choi AM: Regulation of IL-1beta -induced GM-CSF production in human airway smooth muscle cells by carbon monoxide. Am J Physiol Lung Cell Mol Physiol 2003, 284:L50-6.
52. Faffe DS, Whitehead T, Moore PE, Baraldo S, Flynt L, Bourgeois K, Panettieri RA, Shore SA: IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype. Am J Physiol Lung Cell Mol Physiol 2003, 285:L907-14.
53. Stimler NP, Bloor CM, Hugli TE: C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites. Immunopharmacology 1983, 5:251-257.
54. Thangam BE, Venkatesha RT, Zaidi AK, Jordan-Sciutto KL, Goncharov DA, Krymskaya VP, Amrani Y, Panettierijn RA, Ali H: Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. Faseb J 2005, In Press:.
55. . Daffern PJ, Pfeifer PH, Ember JA, Hugli TE: C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995, 181:2119-2127.
56. Elsner J, Oppermann M, Czech W, Dobos G, Schopf E, Norgauer J, Kapp A: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994, 24:518-522.
57. Bischoff SC, de Weck AL, Dahinden CA: Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci U S A 1990, 87:6813-6817.